Please use this identifier to cite or link to this item:
|Title:||Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias||Authors:||Nicolini, F.E.
|Issue Date:||17-Nov-2011||Citation:||Nicolini, F.E., Basak, G.W., Soverini, S., Martinelli, G., Mauro, M.J., Müller, M.C., Hochhaus, A., Chuah, C., Dufva, I.H., Rege-Cambrin, G., Saglio, G., Michallet, M., Labussière, H., Morisset, S., Hayette, S., Etienne, G., Olavarria, E., Zhou, W., Peter, S., Apperley, J.F., Cortes, J. (2011-11-17). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118 (20) : 5697-5700. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2011-07-367326||Abstract:||T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors. © 2011 by The American Society of Hematology.||Source Title:||Blood||URI:||http://scholarbank.nus.edu.sg/handle/10635/124782||ISSN:||00064971||DOI:||10.1182/blood-2011-07-367326|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Apr 12, 2021
WEB OF SCIENCETM
checked on Apr 12, 2021
checked on Apr 10, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.